Edition:
United Kingdom

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

19.64USD
4:53pm BST
Change (% chg)

$-0.27 (-1.36%)
Prev Close
$19.91
Open
$19.75
Day's High
$19.91
Day's Low
$19.18
Volume
34,323
Avg. Vol
365,904
52-wk High
$27.07
52-wk Low
$8.36

Chart for

About

Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The... (more)

Overall

Beta: 3.62
Market Cap(Mil.): $1,019.17
Shares Outstanding(Mil.): 47.45
Dividend: --
Yield (%): --

Financials

  OMER.OQ Industry Sector
P/E (TTM): -- 84.11 32.75
EPS (TTM): -1.46 -- --
ROI: -192.07 1.56 14.38
ROE: -- 2.43 16.07

BRIEF-Omeros Says Entered Into Settlement Agreement And Consent Judgment With Lupin Ltd and unit Lupin Pharmaceuticals - SEC Filing

* OMEROS SAYS ENTERED INTO SETTLEMENT AGREEMENT AND CONSENT JUDGMENT WITH LUPIN LTD, SUBSIDIARY LUPIN PHARMACEUTICALS - SEC FILING

24 May 2018

BRIEF-FDA Grants Breakthrough Therapy Designation To Omeros' Masp-2 Inhibitor Oms721

* FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO OMEROS’ MASP-2 INHIBITOR OMS721 FOR THE TREATMENT OF HIGH-RISK HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY

26 Apr 2018

BRIEF-Omeros Announces Amendment Of Credit Facility

* AMENDED ITS EXISTING CREDIT FACILITY WITH CERTAIN AFFILIATES OF CRG LP

11 Apr 2018

BRIEF-Omeros Q4 Loss Per Share $0.34

* Q4 REVENUE $13.8 MILLION Source text for Eikon: Further company coverage:

01 Mar 2018

BRIEF-European Medicines Agency Issues Orphan Drug Designation Positive Opinion for Omeros' OMS721

* EUROPEAN MEDICINES AGENCY ISSUES ORPHAN DRUG DESIGNATION POSITIVE OPINION FOR OMEROS’ OMS721 IN THE TREATMENT OF IGA NEPHROPATHY

22 Jan 2018

BRIEF-Omeros Reaches Agreement With FDA On OMS721 Phase 3 Trial Protocol For IgA Nephropathy

* OMEROS CORPORATION REACHES AGREEMENT WITH FDA ON OMS721 PHASE 3 TRIAL PROTOCOL FOR IGA NEPHROPATHY

03 Jan 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $120.90 -1.71
Novartis AG (NOVN.S) CHF75.60 +0.10
Pfizer Inc. (PFE.N) $35.94 -0.41
Roche Holding Ltd. (ROG.S) CHF210.40 -1.45
Roche Holding Ltd. (RO.S) CHF214.40 -0.60
Merck & Co., Inc. (MRK.N) $61.08 -0.95
Bayer AG (BAYGn.DE) €98.46 -1.62
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €68.25 -0.43
Eli Lilly And Co (LLY.N) $85.76 -1.12

Earnings vs. Estimates